A groundbreaking pilot study reveals that subtle changes in our body’s metabolism, particularly in fats and lipids, could hold the key to identifying individuals on the verge of a psychotic episode.
Psychosis, a condition characterized by a disconnect from reality, remains one of the most challenging areas in mental health. For clinicians, one of the greatest hurdles is prediction. They can identify individuals at an "ultra-high-risk" (UHR) of developing psychosis based on subtle, early-stage symptoms. Yet, not everyone in this category will go on to experience a full-blown psychotic episode. This uncertainty creates a difficult dilemma: when and how aggressively should we intervene? What if we could move beyond subjective symptoms and find a concrete, biological signpost? A new pilot study published in Translational Psychiatry suggests we may be on the verge of just that, finding clues not in the mind, but in the blood.
A team of researchers embarked on a quest to find predictive biomarkers—measurable biological indicators—that could distinguish UHR individuals who would later develop psychosis from those who would not. Their tool of choice was metabolomics, a powerful technique that provides a high-resolution snapshot of the body’s chemical processes. By analyzing the vast array of small molecules, or metabolites, in a blood sample, scientists can gain unprecedented insight into a person’s physiological state.
The study focused on a group of young adults and adolescents identified as being at ultra-high-risk for psychosis. The researchers collected blood samples and then followed the participants over time. As they had anticipated, a portion of the group, referred to as converters (UHR-P), eventually transitioned to psychosis, while the others did not (UHR-NP). The critical question was: were there any differences in their initial blood chemistry that could have predicted this outcome? To find out, they used a sophisticated technique called Nuclear Magnetic Resonance (NMR) spectroscopy to analyze the metabolic profile of each participant’s serum.
The results pointed toward a fascinating and increasingly important area of brain science: lipid metabolism. The brain is the body’s fattiest organ, with lipids playing a crucial role in everything from cell membrane structure to signaling between neurons. For decades, scientists have theorized that disruptions in these fats could be a root cause of conditions like schizophrenia, a concept known as the "membrane hypothesis of schizophrenia." Previous research has already established links between dysregulated lipid levels and active psychosis, but this new study pushes the boundary further, suggesting these changes are present even before the condition fully manifests.
The researchers discovered a distinct metabolic signature in the UHR individuals who later converted to psychosis. This signature was primarily characterized by alterations in lipoproteins—the particles that transport cholesterol and other fats through the bloodstream. Specifically, they observed differences in the concentrations and compositions of various types of lipoproteins, including High-Density Lipoprotein (HDL), often called "good cholesterol." These weren’t just random fluctuations; they formed a consistent pattern that set the converters apart from the non-converters and a group of healthy controls.
This finding is a potential game-changer. It suggests that the path to psychosis may be paved with metabolic disturbances that can be detected long before the most severe symptoms appear. If these results are validated in larger studies, we can imagine a future where a simple blood test could help clinicians assess a UHR patient’s true risk. This would allow for more targeted and timely interventions, potentially altering the course of the illness entirely.
Furthermore, identifying a specific biological pathway opens up new avenues for treatment. If disrupted lipid metabolism is a key factor, then therapies aimed at correcting it could prove highly effective. This aligns with emerging research on the benefits of omega-3 polyunsaturated fatty acids, which are known to play a vital role in brain health and lipid regulation. Some studies have already suggested that omega-3 supplements may help prevent the transition to psychosis in high-risk individuals. This new metabolomic evidence provides a biological rationale for why such an intervention might work, connecting the treatment directly to the underlying pathology.
Of course, it is crucial to maintain a degree of scientific caution. As a pilot study, the number of participants was relatively small, and the findings must be replicated in larger, more diverse populations. The metabolic signature needs to be refined and validated before it can become a routine diagnostic tool. However, the promise is undeniable.
For years, psychiatry has been striving to move from a purely symptom-based model to one grounded in objective biology. This research represents a significant step in that direction. By looking at the intricate dance of molecules in our blood, we are beginning to understand the systemic nature of mental illness, where the health of the brain is inextricably linked to the metabolism of the entire body. This study doesn’t offer a crystal ball, but it provides a crucial piece of the puzzle, bringing us closer to a future where we can not only treat psychosis but perhaps even prevent it.
References
Avella, M.T., Bertho, G., Giraud, N., Kébir, O., Caradeuc, C., Labad, J., Papiol, S., Schulze, T. G., Krebs, M.-O., Chaumette, B., & Frajerman, A. (2025). Metabolomic biomarkers of psychotic conversion in ultra-high-risk subjects: a pilot study. Translational Psychiatry. https://doi.org/10.1038/s41398-025-03679-8
Chen, C., Deng, Y., Li, Y., Zhang, M., Yu, T., Xie, K., et al. (2024). Network meta-analysis indicates superior effects of omega-3 polyunsaturated fatty acids in preventing the transition to psychosis in individuals at clinical high-risk. International Journal of Neuropsychopharmacology, 27, pyae014.
Dickens, A. M., Sen, P., Kempton, M. J., Barrantes-Vidal, N., Iyegbe, C., Nordentoft, M., et al. (2021). Dysregulated lipid metabolism precedes onset of psychosis. Biological Psychiatry, 89(3), 288–297.
Horrobin, D. F., Glen, A. I., & Vaddadi, K. (1994). The membrane hypothesis of schizophrenia. Schizophrenia Research, 13(3), 195–207.
